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license (http://creativethan a decade. Translation to clinical utility has been limited, especially in Alzheimer’s Disease
(AD). It has become standard practice in the analyses of more than two dozen AD GWAS studies
to exclude the apolipoprotein E (APOE) region because of its extraordinary statistical support, unique
thus far in complex human diseases. New genes associated with AD are proposed frequently based on
SNPs associated with odds ratio (OR), 1.2. Most of these SNPs are not located within the associated
gene exons or introns but are located variable distances away. Often pathologic hypotheses for these
genes are presented, with little or no experimental support. By eliminating the analyses of the APOE-
TOMM40 linkage disequilibrium region, the relationship and data of several genes that are co-located
in that LD region have been largely ignored. Early negative interpretations limited the interest of un-
derstanding the genetic data derived from GWAS, particularly regarding the TOMM40 gene. This
commentary describes the history and problem(s) in interpretation of the genetic interrogation of
the “APOE” region and provides insight into a metabolic mitochondrial basis for the etiology of
AD using both APOE and TOMM40 genetics.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Genetics; APOE; TOMM40; Mitochondria; Alzheimer’s disease short structural variations [SSVs]; Sequencing;Phylogenetic mappingIn a seminar for medical students on the philosophy of
science regarding research methodology, the question was
raised regarding “how to keep-up with massive amount of
literature.” The answer was that, even for an investigator
working in a highly specialized field, it is extremely difficult
to be current. One approach to this dilemma is the strategy
for reading research articles suggested by the late G. Milton
Shy, Professor and Chairman of Neurology, University of
Pennsylvania School of Medicine which was to “forget the
abstract, which is basically the authors’ interpretations butthor. Tel.: 11 919-660-8065.
len.roses@duke.edu
16/j.jalz.2016.03.015
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).rather focus on the data and the published interpretation.
Ask the question of whether the methods and analyses sup-
port the conclusions.”
Even with modern “precision” genetic data, reader inter-
pretations may miss the relevant facts. Specifically, as an
illustrative example, this perspective will explain how inter-
pretations concerning the association of apolipoprotein E
(APOE) ε4 with late-onset Alzheimer’s Disease in 1993
have overlooked such facts in more than two dozen subse-
quent Genome-Wide Association Studies (GWAS)—
without recognizing that the particular SNP associations
could not discriminate APOE alleles. The two APOE
allele-defining SNPs (for APOE ε2, APOE ε3, or APOE
ε4) were not included on the commercial platforms usedimer’s Association. This is an open access article under the CC BY-NC-ND
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pre-dates that 2012 and exclude further analyses of the
“APOE” region, whereas a few newer studies now use the Il-
lumina OmniQuad Array (Fig. 1).
The precise nature of this “interpretation problem” might
be better understood in the context of the rapidly devel-
oping GWAS field between 1997 and 2012. In a 1997 Sci-
ence Commentary entitled “Snipping Away at Genome
Patenting”, Dr. David Cox (a distinguished and popular
geneticist) was quoted as saying that SNP patents could
become “a nightmare” for companies and basic researchers
alike, and that Francis Collins, then head of the National
Genome Research Institute (NHGRI), and others would
like to “head off” [3]. In 1998, the formation of The SNP
Consortium provided an opportunity for industry to work
with the NIH to insure that SNPs would be in the public
domain to promote widespread adoption in research [4].
The SNP Consortium was formed and supported by 10
pharmaceutical companies as a partnership to publish and
distribute enough SNP data into the public domain to
diminish the likelihood of proprietary SNP panels [4].
GlaxoWellcome (GW) Genetics had organized the Con-
sortium and, as SNPs were identified, preceded to test
whether enabling GWAS with new high volume/low cost
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Fig. 1. The region, order, and distance between the TOMM40, APOE and APOC1
KB region containing both the TOMM40 (12.4kb) and APOE (3.6kb) genes show
indicate the position of SNPs from three SNP arrays. SNPs labeled “a” represent th
SNPs labeled “b” are those on the commonly used pre-2012 GWAS studies in AD.
6.0] and was occasionally used pre-2012 in AD GWAS studies. The SNPs marked i
on the Illumina OmniQuad arrays. Prior to 2012 no AD GWAS reported using the I
HumanHap610.quad array that was widely used for GWAS studies contained SNP
rs1160895) or the intragenic region (rs405509). All Affymetrix GWAS arrays conThe association of APOE ε4 with so-called late-onset
sporadic Alzheimer’s disease had been previously discov-
ered in 1992 and published in 1993, a decade before any
commercial GWAS platforms became available [1,2]. In
1997, the GW Genetics Group created a relatively dense
map (at that time) of newly identified human SNPs from
a 2-megabase region on either side of the APOE gene lo-
cus. This region was used to model a GWAS and test
whether a GWAS approach, using the association of
APOE and AD, would be easily recognized. This proof
of concept was based on a simple question: could future
GWAS screening identify the location of the APOE locus
associated with age of onset distributions of AD if there
were no prior knowledge [5–7].
The APOE locus was confirmed—including SNPs from
APOE and SNPs within PEREC1 (an expressed gene later
discovered to be TOMM40) and APOC1. Specific allele-
determining APOE SNPs as well as SNPs from the other
recognized genes and noncoding SNPs in the linkage
disequilibrium (LD) region provided very strong stati-
stical evidence of association. Eventually, the Human
Genome Project clearly defined this region as having
strong LD.
GW had also collected well-phenotyped clinical cohorts
with banked deoxyribonucleic acid (DNA) for 17 different






























genes are illustrated on the upper 30kp map. The lower map enhances the 20
n in a 20kb region below (black5exons; white5introns). The arrows below
e newest array [Illumina OmniQuad] coming into limited use post-2012. The
The SNP labeled “c” is the only representative in this LD region [Affymetric
n the red boxes are the APOE allelic determining SNPs, and are present only
llumina OmniQuad arrays containing these two SNPs directly. The Illumina
s located within the introns of TOMM40 (rs157580, rs2075650, rs8106922,
tained only the single rs1160985 SNP located in intron 5 of TOMM40.
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purchased from several technology companies to perform
parallel beta pilot testing. SNP genotyping platforms were
directly compared using the same DNA samples to deter-
mine functional characteristics of each platform.
By 2006, GSK had completed GWAS studies from seven
different disease cohorts, using several different platforms.
The results clearly demonstrated that SNPs from immediate
neighbors within the “APOE” locus had a unique association
with AD. A similarly robust association was not observed at
anymeasured locus in the other six diseases. It was clear that
this strategy would not be generalized. These negative
GWAS studies were not increased in size to detect small sig-
nals and were concluded in 2007. Two of the commercial
platforms (without the two APOE allele-determining
SNPs) became widely used as the winning platforms.
GWAS became the hot area of research throughout medicine
fueled by commercial SNP panels. The results from the
“APOE” region were (and still are) unique. Instead of simply
adding more patients in more diseases, at an extraordinary
cost, GSK genetics initiated a post-GWAS strategy using
phylogenetic mapping to dissect the “APOE” linkage
disequilibrium (LD) region.
GWAS has provided massive information to the public da-
tabases: yet, it should be considered whether the data are
representative of a gene or actually an LD region. Identifica-
tion of a “gene” located near a particular SNP on the platform
gets reported frequently from GWAS from many diseases,
including associated press releases. Historically, microsatel-
lite markers for genetic mapping had been anchored to genes.
However, with the success of the Human Genome Project, ge-
netic markers can be accurately mapped to primary DNA.
Currently, GWAS is transitioning to next-generation
sequencing (NGS), but it has unfortunately become second
nature to refer to specific SNPs with low odds ratio associa-
tion data as “disease genes,” even if the SNP is at some dis-
tance from the nominated gene. As will be discussed below,
even common complete NGS technologies in 2016 do not
accurately measure the length of short tandem repeat (STR)
sequences, which may indeed be more important to define
common complex diseases from more than a million variable
structural variations in the human genome. Recently, there
has been some progress in measuring repeat length sequences
accurately, but expectations have been high for this technol-
ogy for the past several years. One of the experimental data
sets being investigated is the TOMM400523 locus. When Dr.
David Botstein joined the Board of Pac-Bio in 2012, he stated
in the press release [8]“We are moving toward an exciting era where the cost of
producing sequencing information is going down, and
now the emergence of the high-quality, multi-kilobase
sequence will be a double game changer. Even with
today’s advanced sequencers, a lot of good biology is
being left on the table because we cannot fully assemble
genomes for the many organisms for which there is no
reference, or becausewe are missing difficult to sequenceregions of critical variation. Pacific Biosciences’ long-
read technology offers the field something that currently
does not otherwise exist—the ability to create high
quality de novo assemblies, improve re-assemblies for
complex organisms, and understand DNA modifications
within sequences.”1. TOMM40 and AD
In 2005, GSK was unable to fully sequence the
“APOE” LD region for phylogenetic mapping purposes.
A variable length of region in intron 6 of the TOMM40
gene could neither be sequenced in two GSK sequencing
laboratories nor in 5 of 6 commercial sequencing com-
panies. However, one out-sourced laboratory accom-
plished the sequencing successfully (Polymorphic
Technologies, Inc.; Alameda, CA). Using their specialized
methods (now validated), all the SNPs and multiple repeat
sequences in the LD region were sequenced. Sanger
sequencing protocols were validated to map the DNA
strands and to begin defining variable nucleotide length
repeats on the same chromosomal strand (cis). GSK
used phylogenetic mapping to place evolutionary variants
within the TOMM40-APOE-APOC1 LD region in well-
defined clades. Fig. 2A depicts the phylogenetic map, as
published, for an Arizona Alzheimer’s Disease Research
Center (ADRC) AD cohort [9]. Similar lengths of polyT
repeats at the TOMM400523 locus were characteristic of
several major phylogenetic clades in another independent
Caucasian cohort (Canadian). The clusters of polyT length
polymorphisms were subsequently associated with the age
of onset distributions, using a prospectively ascertained
clinical AD cohort followed at the Bryan ADRC.
Fig. 2B illustrates the phylogenetic clade intersection
which separates the ancestral Long TOMM400523 alleles
from the separate VL and S clades [9–11].
The frequency of major clusters of polyT length in ma-
jor clades differs in multiple ethnic groups [10,11]. The
accuracy of the polyT lengths using validated methods
(Polymorphic DNA Inc. for research use, and Quest
Diagnostics in more than 22,000 clinical trial tests under
Food and Drug Administration standards) allowed the
observation in African-Americans of new cis-haplotypes
that had not been observed in multiple Caucasian popula-
tions studied at more than 50 centers in the United States,
United Kingdom, Germany, Switzerland, Australia, and
Russia (Siberia) participating in the TOMMORROW clin-
ical trial testing an age-dependent risk algorithm using
TOMM400523, APOE, and age of onset [12,13].
Within Caucasian cohorts from around the world, the
pattern of phylogenetic maps was shown to be highly
reproducible [9,13]. More than 28 different polyT
lengths were mapped to several large evolutionary
clades. The large clades were grouped into three polyT
length clusters which were labeled short (S 5 ,20 T’s),
long (L 5 20–30), and very long (VL 5 30) polyT
Fig. 2. (A) TOMM400523 poly-T length polymorphisms evolved independently over time and on different genetic backgrounds at a single highly variable
locus. Each major clad is characterized by new mutations based on the repeat sequence common in that clade [9]. (B) Another view of the Arizona cohort
mapped on new recent TreeLink Software. [22] The use of TreeLink Software allows the major clades containing VL and S “clades” to be visualized as
separately branching from the main evolutionary L clade at two distinct times. Horizontal distances are directly from the software and are commensurate
with evolutionary time scale. This illustrates that the major clades differ in the evolutionary timing of formation and contains subsequent chromosomal
SNPs [sometimes referred to as “mutations”] according to the S, L and VL polyT lengths.
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demonstrated that: S lengths are in phase cis to APOE
ε3 and APOE ε2 alleles; the L alleles segregate cis to
APOE ε4 chromosomes. Nearby SNPs that are also
mapped within each of these large clades also may
reflect association to age of onset distributions. The
TOMM400523 polyT lengths connected to APOE alleles
could now allow TOMM400523-APOE cis-haplotypes to
define age of onset distributions for .97% of Caucasians,
connecting the clinical phenotype of AD to APOE
genotypes, as was reported in 1993 [2,12]. The major
distinction of this work is not simply the association of
the region with AD but the informative estimates of risk
for .97% of individuals. It is important to note that there
are three additional distributions of APOE ε3/3 carriers
(S-S, S-VL, and VL-VL) that are now providing differential
age of onset information using TOMM400523 that were not
available using APOE ε4 alone (4/4, 3/4, and 2/4). Both
APOE ε2/2 (1%–2%) and APOE ε2/4 (1%–2%) are
uncommon genotypes in Caucasian AD patients, so there
are not yet enough age of onset data points to provide a
distribution in clinical cohorts, but such data will be
available and shared publically when the TOMMORROW
clinical delay of mild cognitive impairment onset trial is
completed [12]. The TOMM400523/APOE cis-haplotypes
are even more informative, including data from several
ongoing studies of other ethnicities, including African-
Americans, that recognize cis-haplotypes rarely encountered
in Caucasians [10–12,15].2. Precision versus accuracy
Between 1993 and 1995, most AD geneticists were
skeptical of the role of APOE ε4 in sporadic AD [14]. How-
ever, as APOE isotyping (using gel electrophoreses to
distinguish the apoE proteins) was available within several
hospitals (primarily European), the APOE ε4 association
with AD was confirmed rapidly [15]. The association has
held up remarkably as a confirmed risk factor over the years
[15–18]. However, it was recommended in 1997 by an NIH
Conference Panel that APOE ε4 should not be used as a
diagnostic in clinical practice [19]. Because Duke Univer-
sity owned the issued patent on the association of APOE ε4
and AD, Duke made the decision to exclude the two SNPs
that determine the APOE alleles from the developing
GWAS platforms so that the two SNPs would not be used
inappropriately as a clinical genetic test for a disease with
inadequate therapy but would be available for use in
research and as a clinical pharmacogenetic test [20]. This
did discourage the use APOE genotyping as a commercial
medical diagnostic product. However, when the early
SNP platforms were being beta-tested, and until 2012, com-
mercial GWAS platforms used for AD studies contained
neither coding SNPs nor any SNPs from introns of APOE
(Fig. 1). The use of other SNPs in the so-called “APOE”
LD region allowed precise location to the LD area butwere not accurate for expanding to APOE genetics [20].
Four of the 5 SNPs on the most used platforms before
2012 used noncoding SNPs outside the APOE locus to
impute the LD region and could not make an accurate
call of specific APOE alleles, as measured by the two
SNPs that define the gene variance.
The first wave of GWAS studies in AD, before 2012, rep-
resents other alleles that may be linked to APOE but are not
direct assessments of APOE ε4 alleles [20,21]. The “APOE
region” is the common slang for relating association data
that actually represent the LD region and not APOE
alleles for any individual. When genetic rigor is applied,
the data represent TOMM40 SNPs more accurately than
APOE. Statements made in 2012 about separating an
“APOE” effect from a TOMM40 effect are not possible,
because neither the TOMM400523 alleles or the APOE
alleles were specifically studied [22]. The GWAS data are
fine for association within the LD region but do not test or
recognize specific cis-haplotypes available fromphylogenetic
maps. A clinically important difference is that TOMM400523
genotyping is more informative in .97% of the Caucasian
population, then only 29% of APOE ε4 carriers and, for the
first time,APOE ε3/3 patients can be dividedwith two specific
APOE ε3-TOMM400523 cis-haplotypes into three groups (S/S,
S/VL, and VL/VL) with distinct age of onset curves [9,12].
This does not mean that apoE isoforms are neither
involved in the pathogenesis of AD nor does it mean that
TOMM40 is the gene. It does suggest relevance of two adja-
cent genes to the rate of clinical expression of AD. The
evidence for a known functional interactions within human
metabolism is emerging, beginning with the differential ef-
fects of APOE isoforms on mitochondrial dynamics, differ-
ential effects on mitochondrial metabolism mitochondria,
and decreased mitochondrial dynamic functions [23]. Using
later SNP platforms with APOE allele-specific SNPs is still
less robust than phased phylogenetic mapping. The genetic
association of TOMM400523/APOE cis-haplotypes is far
more accurate to translate to individuals in the population
than measuring a few SNPs from TOMM40 and calling it
“APOE” data. For the first time, three different ages of onset
distribution can now be attributed to the largest group of AD
patients, APOE ε3/3 (60% of Caucasians), by delineating
three TOMM400523 sub-classes (S-S, S-VL, and VL-VL),
raising the informative data to .97% of individuals,
compared to 29% with APOE4 alone [12].
TOMM400523 association with AD age of onset has
received the same skeptical welcome that had been the
case for APOE in the early 1990s [3,16]. In one early
“Online First” Editorial published in August 2012 it was
stated: “Not only did genetic variants within APOE show
association with AD but single-nucleotide polymorphisms
(SNPs) around the locus also presented strong associations
with the disease” [22]. The operative word is “also,”
because the two dozen GWAS studies that had been re-
ported by that time did not measure the two SNPs
that define APOE alleles. The authors also stated that
A. Roses et al. / Alzheimer’s & Dementia 12 (2016) 687-694692“it is very difficult to attribute a genetic and APOE-
independent role of TOMM40.” This is especially true
when APOE alleles and TOMM400523 are not specifically
measured. Because the TOMM400523 region can now be
phased on the same DNA strand, the cis-haplotypes data
can be far more accurate and informative than genotypes
or SNP haplotypes. Even newer SNP platforms that contain
the two specific APOE SNP alleles cannot provide phased
chromosomal relationships.
AD GWAS articles had discussed only the “APOE” re-
gion, ignoring the TOMM400523 data although four of the
five SNPs studied were located within TOMM40. Clearly,
much of the field did not realize what they were actually
measuring. To make life easier in finding new genes, most
GWAS studies excluded the entire “APOE” LD region in
their analyses. [21] However, the AD GWAS published by
our group at GSK discussed the possibility of another
gene, later defined as TOMM40 but present in our 1998
article as PEREC-1, before it was known that this was the lo-
cus for the translocase of the external mitochondrial mem-
brane channel [5,20].
It is inaccurate to attribute all late-onset AD genetics to
APOE (or TOMM40). However, it must be realized that it
is also inaccurate to depend solely on small statistical effects
to nominate a gene. GWAS uses a common correction for a
million SNP tests to generate statistical associations. A
designated gene that is near to a specific SNP or several
SNPs may be precise localization, perhaps even within
LD. Accuracy and precision are not one in the same.
Although the precise molecular pathogenesis affecting mito-
chondria leading the increased risk of AD remains undeter-
mined, the “precision” of localization to the “APOE LD
region” has diverted consideration of fine mapping of the
actual variants within the LD region over the past 5 years.
TOMM400523 is a structural variation locus that is coded
at a precise genetic locus with more than two dozen length
variations. There is sufficient variation to be associated
with individual age of onset distributions—not just associa-
tion to large groups of patients labeled as AD without taking
into account thew10% error in AD diagnosis in living pa-
tients. The important point is that APOE became “the” refer-
enced gene rather than simply an important gene in a broader
view of the LD field. This has diverted consideration of the
LD genetic findings and hampered efforts to develop new
therapeutic options to ease the burden of AD. Being precise
in locating the “field,” but inaccurate and off-target is of little
benefit.3. Considerations and speculations
As a broader view important to GWAS interpretations in
other diseases, imputation of a nearby SNP from GWAS and
assigning a “gene name” to it needs to be carefully noted
[21,24–26]. Naming such genes misses the point that other
SNPs and structural variants, like the polyT variants of
TOMM400523, can provide a clearer view of the nearbyfield and other more precise data can be observed within
the field [9,12,26–28].
Perhaps, the most important observations with respect to
TOMM40 and the association of age of onset of AD is that
there are variable length polyT repeats at a single locus
within intron 6 of TOMM40 which carry the critical pheno-
type of age of onset. The distribution of this single nucleo-
tide repeat is directly related to the AD phenotype. The
pathophysiology field for AD is broader than simply amy-
loid or tau deposition. APOE ε4 is commonly imputed as
the important gene and is certainly clearly involved as a sig-
nificant biological contributor. Similarly, the TOMM400523
variants may be involved with alternative splicing or
mRNA expression [27,30].
The future may have new preventative and treatment
drugs with different efficacy pharmacogenetic profiles,
dependent on the cis-haplotypes of TOMM400523 and
APOE [12]. TOMM40 is the main channel through which
proteins and peptides must traverse to support the dynamic
functions of mitochondria, identifying pathogenic factors
than may result through changes in mRNA expression
and/or alternative splicing may be critical in the future
[27–30]. We know that many aggregating proteins bind
and traverse through Tom40 protein channel and
aggregate within the channel. Besides apoE4 and apoE3,
there are more than 30 proteins associated pathologically
with brain plaques in AD. APP and amyloid may exert
catalyzing effects on the rate of disease expression based
on heterogeneous interactions with the mitochondrial
channel through which it is meant to travel [30]. Studying
the amyloid protein as a component of the pathogenesis is
critical, but we need to know the right drug target for drug
discovery [31]. None of the previously mentioned GWAS
studies ever demonstrated statistical association attributed
to the APP gene [31–34].
Tom40 dysfunction has been noted in Parkinson’s disease
and may also relate to Huntington’s disease [33,34].
Unfortunately, there are many degenerative neurological
diseases in which Tom40 remains unstudied. Mitochondrial
dynamics are affected by apoE4 differently than by apoE3
[35–40]. The evidence for mitochondrial effects in the
brain, particularly in glucose and oxygen utilization, is
quite clear and evident from many positron imaging
experiments [41]. Oxygen and glucose are primarily pro-
cessed by mitochondria, especially in the brain. ApoE iso-
forms and Tom40 variants may affect that metabolism
probably from birth. The course of AD may be accelerated
by the inheritance of APOE ε4, with plaques and tangles
representing visible damage. Finally, TOMM400523 is
related to AD pathogenesis based on the .97% informative
age of onset distributions. ApoE, amyloid, and synuclein pro-
teins are interactive with Tom40 [33,42]. The Tom40 protein
forms the channel by specific protein interactions involving
several intrinsic proteins and multiple signaling proteins
[43,44]. Basic science studies focusing on the structure
and function of TOMM40 and its associated interactions
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will accelerate drug discovery and development
from determining the role of mitochondria and relevant
mechanisms of pathogenesis.RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed the Alz-
heimer’s Disease GWAS literature using traditional
(e.g., PubMed) sources, as well as press releases
with respect to the interpretation of limited genetic
data. The content of commercial GWAS single-
nucleotide polymorphism (SNP) platforms and the
designation of small odds ratios as evidence for
declaring a new “AD gene” of small effect was the
primary focus.
2. Interpretation: Our findings highlighted the limita-
tions of the GWAS platforms compared to phyloge-
netic mapping of sequenced data. The data utilized
for genetic identity were contrasted to phylogenetic
mapping of the APOE and TOMM40 linkage disequi-
librium region. This LD region has been acknowl-
edged as robust, but is usually formally excluded
from additional genetic analyses in order to focus
on new “genes.”
3. Future directions: This Perspective proposes a ge-
netic framework for the confirmation of “new
gene” hypotheses using sequencing of proposed LD
regions and highlighting the role of highly polymor-
phic short tandem repeat sequences related to struc-
tural variants located throughout the genome.References
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